期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 20, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms20061388
关键词
auditory brainstem response; congenital cytomegalovirus infection; hearing dysfunction; severity; valganciclovir
资金
- Ministry of Health, Labour and Welfare of Japan [H23-Jisedai-Ippan-001, H25-Jisedai-Shitei-003]
- Japan Agency for Medical Research and Development, AMED [15Agk0110003h0103, 16gk0110021h0101, 17gk0110021h0101, 18gk0110021h0001]
- Kawano Masanori Memorial Foundation for Promotion of Pediatrics [2018]
Although earlier studies have shown that antiviral treatment regimens using valganciclovir (VGCV) improved hearing function in some infants with congenital cytomegalovirus (CMV) infection; its efficacy on the severity of hearing dysfunction is unclear. We conducted a prospective study among 26 infants with congenital CMV infections from 2009 to 2018. Oral VGCV (32 mg/kg/day) was administered for 6 weeks (November 2009 to June 2015; n = 20) or 6 months (July 2015 to March 2018, n = 6). Hearing function was evaluated by measuring the auditory brainstem response before VGCV treatment and at 6 months. Hearing dysfunction, defined as a V-wave threshold >40 dB, was categorized into: most severe, >= 91 dB; severe, 61-90 dB; and moderate, 41-60 dB. Hearing improvement was defined as a decrease of >= 20 dB from the pretreatment V-wave threshold. Of 52 ears in 26 infants with congenital CMV infection, 29 (56%) had hearing dysfunction, and of 29 ears, 16 (55%) improved after VGCV treatment. Although, 16 (84%) of 19 ears with moderate or severe hearing dysfunction improved after treatment (p < 0.001), 10 ears with the most severe form did not. In conclusion, VGCV treatment is effective in improving moderate and severe hearing dysfunction in infants with congenital CMV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据